首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症

市場調查報告書

商品編碼

1623772

卵巢癌診斷市場規模、佔有率、成長分析，按癌症類型、測試類型、地區分類 - 產業預測，2025-2032 年

Ovarian Cancer Diagnostic Market Size, Share, Growth Analysis, By Cancer Type (Epithelial Tumor Diagnostics, Germ Cell Carcinoma Tumor Diagnostics), By Test Type (Imaging, Blood Test), By Region - Industry Forecast 2025-2032

出版日期: 2024年12月26日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

卵巢癌診斷的全球市場規模預計在2023 年達到19 億美元，從2024 年的20 億美元成長到2032 年的30.5 億美元，預計在預測期內（2025-2032 年）複合年成長率為5.4% 。

卵巢癌，尤其是上皮性卵巢癌，是一個嚴重的健康問題，是全球女性癌症相關死亡的第五大原因。卵巢癌診斷市場的快速成長是由多種因素推動的，包括創新治療方法、癌症研究資金的增加、健康意識的提高以及老年女性人口的增加。診斷技術的進步為加強早期檢測提供了新的機會。目前，現有方法存在顯著差距，往往只能在晚期階段才能識別出疾病。此外，政府和機構努力開發方便、及時的診斷解決方案對於市場成長也至關重要。這樣的生態系凸顯了卵巢癌早期檢測和顯著改善治療結果的潛力。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東/非洲
- 海灣合作理事會國家
- 南非
- 其他中東/非洲

競爭資訊

前5名企業對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司簡介
- 產品系列分析
- 按細分市場分類的佔有率分析
收益與前一年同期比較（2022-2024）

主要企業簡介

Illumina
Thermo Fisher Scientific
Roche
Siemens Healthineers
Abbott
QIAGEN
Hologic
Beckman Coulter
Becton, Dickinson and Company（BD）
Bio-Rad Laboratories
Quest Diagnostics
Myriad Genetics
Genomic Health（Exact Sciences）
Agilent Technologies
PerkinElmer Inc.
bioMerieux SA
Merck KGaA
GE Healthcare
Sysmex Corporation
NanoString Technologies

結論和建議

簡介目錄

Product Code: SQMIG35F2014

Global Ovarian Cancer Diagnostic Market size was valued at USD 1.9 billion in 2023 and is poised to grow from USD 2 billion in 2024 to USD 3.05 billion by 2032, growing at a CAGR of 5.4% during the forecast period (2025-2032).

Ovarian cancer, particularly epithelial ovarian cancer, is a significant health concern and the fifth leading cause of cancer-related death among women globally. The surge in the ovarian cancer diagnostics market is driven by several factors, including innovative treatment modalities, increased funding for cancer research, heightened health awareness, and a growing population of older women. Advancements in diagnostic technologies present new opportunities to enhance early detection, currently a major gap in existing methods that tend to identify the disease only at advanced stages. Additionally, government and institutional efforts to develop convenient and timely diagnostic solutions are crucial for market growth. This ecosystem underscores the potential for significant improvements in early detection and treatment outcomes in the ovarian cancer landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ovarian Cancer Diagnostic market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ovarian Cancer Diagnostic Market Segmental Analysis

Global Ovarian Cancer Diagnostic Market is segmented by cancer type, test type, end user and region. Based on cancer type, the market is segmented into epithelial tumor diagnostics, germ cell carcinoma tumor diagnostics, stromal carcinoma tumor diagnostics and others. Based on test type, the market is segmented into imaging, blood test, biopsy and others. Based on end user, the market is segmented into hospital associated labs, independent diagnostic laboratories, cancer research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ovarian Cancer Diagnostic Market

The Global Ovarian Cancer Diagnostic market is being significantly propelled by the increasing population of elderly women, which correlates with a higher incidence of ovarian cancer cases. This demographic shift is prompting governments to enhance healthcare initiatives aimed at cancer detection and treatment. Moreover, rising healthcare awareness among individuals is contributing to market expansion, as more patients seek diagnostic solutions and innovative treatments, including established drugs like Bevacizumab (Avastin) and Pazopanib (Votrient). Concurrently, the expiration of patents for existing medications is paving the way for new entrants into the market and stimulating the adoption of innovative combination therapies. Additionally, ongoing research and development, supported by both governmental and private funding, further enrich the market landscape, creating opportunities for advancements in ovarian cancer diagnostics and treatments.

Restraints in the Global Ovarian Cancer Diagnostic Market

One significant restraint affecting the global ovarian cancer diagnostic market is the widespread ignorance surrounding the symptoms of ovarian cancer. Often, these symptoms are overlooked or misdiagnosed, as they can easily be mistaken for those associated with other medical conditions. This lack of awareness leads to delayed detection and diagnosis, severely impacting treatment outcomes. As a result, the progression of ovarian cancer can worsen, complicating the clinical management of the disease. Ultimately, this scenario not only hinders patient outcomes but also impacts market growth, as timely diagnosis and treatment are crucial for effective management of ovarian cancer.

Market Trends of the Global Ovarian Cancer Diagnostic Market

The global ovarian cancer diagnostic market is witnessing a significant upward trend driven by the growing understanding of cancer biomarkers and advancements in detection technologies. Enhanced biotechnological innovations have facilitated the identification and commercialization of potential biomarkers, creating new avenues for effective diagnosis and treatment of ovarian cancer. This surge in biomarker research, coupled with improved diagnostic equipment, is empowering healthcare providers with tools for early detection, thus enhancing patient outcomes. As a result, the market is poised for substantial growth as stakeholders invest in the development and implementation of novel diagnostic solutions to meet the rising demand for precision oncology.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Case Study Analysis

Global Ovarian Cancer Diagnostic Market Size by Cancer Type & CAGR (2025-2032)

Market Overview
Epithelial Tumor Diagnostics
Germ Cell Carcinoma Tumor Diagnostics
Stromal Carcinoma Tumor Diagnostics
Others

Global Ovarian Cancer Diagnostic Market Size by Test Type & CAGR (2025-2032)

Market Overview
Imaging
- Ultrasound
CT Scan
MRI Scan
PET Scan
- Others
Blood Test
CA125
HER2
BRCA
CEA
ER & PR
KRAS Mutation
- Others
Biopsy
Others

Global Ovarian Cancer Diagnostic Market Size by End User & CAGR (2025-2032)

Market Overview
Hospital Associated Labs
Independent Diagnostic Laboratories
Cancer Research Institutes
Others

Global Ovarian Cancer Diagnostic Market Size & CAGR (2025-2032)

North America (Cancer Type, Test Type, End User)
- US
- Canada
Europe (Cancer Type, Test Type, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Cancer Type, Test Type, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Cancer Type, Test Type, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Cancer Type, Test Type, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Illumina
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beckman Coulter
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (BD)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genomic Health (Exact Sciences)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NanoString Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments